859026-99-6

Basic information

• Product Name: Benzoic acid, 4-methyl-3-(trifluoromethyl)-, ethyl ester
• Synonyms: ethyl 4-methyl-3-trifluoromethylbenzoate;ethyl 4-methyl-3-(trifluoromethyl)benzoate;4-Methyl-3-trifluoromethyl-benzoic acid ethyl ester
• CAS NO: 859026-99-6
• Molecular Formula: C11H11F3O2
• Molecular Weight: 232.202
• Mol File: 859026-99-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 248.7±40.0 °C(Predicted)
• Density: 1.199±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Benzoic acid, 4-methyl-3-(trifluoromethyl)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-methyl-3-(trifluoromethyl)-, ethyl ester(859026-99-6)
• EPA Substance Registry System: Benzoic acid, 4-methyl-3-(trifluoromethyl)-, ethyl ester(859026-99-6)

Safety Data

• Hazardous Substances Data: 859026-99-6(Hazardous Substances Data)

Upstream product

• 261952-01-6 4-methyl-3-(trifluoromethyl)benzoic acid 
• 64-17-5 ethanol 

Downstream Products

• 859027-00-2 4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-benzoic acid ethyl ester 
• 859027-02-4 4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) benzoic acid 
• 859027-01-3 4-bromomethyl-3-trifluoromethyl-benzoic acid ethyl ester 

Relevant articles and documents

Synthesis, crystal structure, and spectral characterization of flumatinib mesylate

Flumatinib mesylate, a 3-substituted picolinamide derivative structurally similar to imatinib mesylate, was prepared. The compound was characterized by infrared, ultraviolet, NMR, and electrospray ionization-mass spectra together with X-ray crystal struct

Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors

A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bc

AMIDE DERIVATIVE AND MEDICINE

The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula [1]: (wherein R1 represents -CH2-R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.